Previous 10 | Next 10 |
Guardant Health ( NASDAQ: GH ) announced Wednesday that UnitedHealthcare, the insurance arm of UnitedHealth Group ( UNH ), has decided to cover the company’s Guardant360 CDx liquid biopsy test for all its commercial policies. The new coverage decision allows reimbursement f...
Guardant360 CDx test is now covered under UHC commercial policies for all FDA-approved biomarker confirmation indications in patients with advanced or metastatic breast or non-small cell lung cancer Nation’s largest health insurer now covers Guardant360 CDx liquid biopsy for compre...
Summary Structure Therapeutics raised $161 million in a successful US IPO to support development of its oral therapeutics portfolio aimed at chronic metabolic and pulmonary diseases. CS Pharmaceuticals entered a $336 million agreement for greater China rights to a PRS inhibitor, Bersipo...
- Collaboration is Guardant Health’s first to explore both tissue- and blood-based assays as companion diagnostics (CDx) Guardant Health Inc. (Nasdaq: GH), a leading precision oncology company, and AnHeart Therapeutics, a clinical-stage global biopharmaceutical company committed to...
Nearly all of Illumina’s claims to be dismissed as filed Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, issued the following statement today regarding the favorable recommendation by U.S. District Court Magistrate Judge Christopher J. Burke that nearly ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2022 after market close on Thursday, February 23, 2023. Company management will be webcasting a corresponding conference call beginning a...
Suite of AI-powered expert systems and discovery platforms will be developed internally and through outside partnerships First application using AI-backed image analysis developed by Lunit® for Guardant360 TissueNext TM PD-L1 test improves biomarker detection by >20% in NSCLC ...
Summary BNGO reported preliminary Q4 results, showing acceptable core business performance. Aggressive expansion into capital-intensive markets could put significant pressure on BNGO's balance sheet. Recently-introduced LDTs will likely have a limited impact on revenue growth. ...
Guardant Health ( NASDAQ: GH ) said that the U.S. Food and Drug Administration (FDA) approved its Guardant360 CDx liquid biopsy test as a companion diagnostic for use with Menarini's medicine Orserdu. Guardant360 can be used now to identify patients with advan...
ESR1 mutations, a known driver of resistance to standard endocrine therapy, are present in up to 40% of ER+, HER2- advanced breast cancers 1 ORSERDU (elacestrant) is first FDA-approved endocrine therapy innovation in more than 20 years, specifically addressing ESR1 mutations, a major ...
News, Short Squeeze, Breakout and More Instantly...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2024 after market close on Wednesday, August 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Ti...
Running on Guardant Infinity™ smart liquid biopsy platform, new Guardant360 test covers over 10 times more genes, including all guideline-recommended genomic biomarkers across advanced solid tumors, and quantifies tumor burden with 10 times higher sensitivity Upgraded test covered ...
2024-07-21 23:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...